SkinBioTherapeutics plc (LON:SBTX – Get Free Report)’s share price was up 1.9% during mid-day trading on Tuesday. The company traded as high as GBX 6.50 and last traded at GBX 5.50. 789,433 shares traded hands during trading, a decline of 73% from the average session volume of 2,872,288 shares. The stock had previously closed at GBX 5.40.
SkinBioTherapeutics Stock Performance
The company has a debt-to-equity ratio of 11.77, a current ratio of 6.14 and a quick ratio of 10.01. The firm has a fifty day simple moving average of GBX 8.29 and a 200 day simple moving average of GBX 9.46. The company has a market cap of £14.25 million, a price-to-earnings ratio of -34.38 and a beta of 0.10.
About SkinBioTherapeutics
SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.
Recommended Stories
- Five stocks we like better than SkinBioTherapeutics
- UnitedHealth Beats on Earnings, But Investors Question Growth Path
- Swarm Economics: Can XTEND AI Robotics Deliver at Scale?
- Tesla Wants to Make Its Own Chips—What Could Go Wrong?
- IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver?
Receive News & Ratings for SkinBioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SkinBioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
